SpyGlass Pharma, Inc. (SGP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, SpyGlass Pharma, Inc. (SGP) has a cash flow conversion efficiency ratio of -0.064x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.84 Million) by net assets ($232.36 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. View current stock price of SpyGlass Pharma, Inc. for real-time trading data and today's change.
SpyGlass Pharma, Inc. - Cash Flow Conversion Efficiency Trend (2023–2025)
This chart illustrates how SpyGlass Pharma, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see SpyGlass Pharma, Inc. stock valuation for the company's overall valuation and market capitalisation.
SpyGlass Pharma, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SpyGlass Pharma, Inc. ranked by their cash flow conversion efficiency. Also see SpyGlass Pharma, Inc. total assets for a full breakdown of the balance sheet.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cello World Limited
NSE:CELLO
|
0.010x |
|
Archicom S.A.
WAR:ARH
|
0.087x |
|
Jiangsu Yawei Machine Tool Co Ltd
SHE:002559
|
0.057x |
|
Rackspace Technology Inc
NASDAQ:RXT
|
-0.004x |
|
L&C Bio Co. Ltd
KQ:290650
|
0.014x |
|
Aspen Group
AU:APZ
|
0.036x |
|
Dynamatic Technologies Limited
NSE:DYNAMATECH
|
0.068x |
|
Power Solutions International, Inc. Common Stock
NASDAQ:PSIX
|
0.279x |
Annual Cash Flow Conversion Efficiency for SpyGlass Pharma, Inc. (2023–2025)
The table below shows the annual cash flow conversion efficiency of SpyGlass Pharma, Inc. from 2023 to 2025. Review financial flexibility index of SpyGlass Pharma, Inc. to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-98.84 Million | $-32.70 Million | 0.331x | -9.16% |
| 2024-12-31 | $-60.47 Million | $-22.03 Million | 0.364x | -2.14% |
| 2023-12-31 | $-32.99 Million | $-12.28 Million | 0.372x | -- |
About SpyGlass Pharma, Inc.
SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intra… Read more